诺华公司Novartis（NVS）2019年年度报告（英文版）（343页）.pdf

1、Annual Report 2019 Annual Report 2019 I Chairmans letter Novartis delivered strong performance in 2019. New product launches together with a disciplined focus on costs and operational efficiency helped us in crease sales, operating income and operating profit margin. Looking ahead, we are well posit

2、ioned to continue our growth trajectory as we pursue our goal of driving sci- ence-based medical innovation. With the successful spin-off of our former eye care divi- sion, Alcon, in early 2019, we concluded a major step in our portfolio transformation to create a more focused medicines company. We

3、are active in disease areas with high un met needs and have a leading portfolio of highly innovative drugs, including recent ly launched breast can- cer therapy Piqray, eye care treatment Beovu, multiple sclerosis drug Mayzent, and our gene therapy Zolgensma for spinal muscular atrophy. Going forwar

4、d, we continue to strive for business excel- lence across all our divisions and functions. We are con- tinually streamlining our business services and produc- tion platforms. We are also introducing innovative digital technologies to support our research, development and production efforts. As the d

5、igitization of our operations and the overall healthcare industry gains pace, we are also taking action to minimize cyber risks and protect patient data. As a global healthcare leader, we are working to spear- head cutting-edge medical development. Our recent moves in the areas of gene therapies, ra

6、dioligand thera- pies and digital health reflect our position at the forefront of scientific discovery. To develop breakthrough thera- pies that can help change the practice of medicine, we are intent on attracting the best industry talent, collabo- rating with leading technology partners, and pursu